JP2016513714A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513714A5 JP2016513714A5 JP2016502572A JP2016502572A JP2016513714A5 JP 2016513714 A5 JP2016513714 A5 JP 2016513714A5 JP 2016502572 A JP2016502572 A JP 2016502572A JP 2016502572 A JP2016502572 A JP 2016502572A JP 2016513714 A5 JP2016513714 A5 JP 2016513714A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- group
- disease
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 25
- 108090000190 Thrombin Proteins 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 229960004072 thrombin Drugs 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 21
- 239000003814 drug Substances 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 9
- 208000007536 Thrombosis Diseases 0.000 claims 8
- 125000002947 alkylene group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 102000001399 Kallikrein Human genes 0.000 claims 4
- 108060005987 Kallikrein Proteins 0.000 claims 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims 4
- 125000004474 heteroalkylene group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 125000005647 linker group Chemical group 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- -1 oxetanyl compound Chemical class 0.000 claims 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 claims 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- 206010014513 Embolism arterial Diseases 0.000 claims 1
- 206010014522 Embolism venous Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102100038297 Kallikrein-1 Human genes 0.000 claims 1
- 101710176219 Kallikrein-1 Proteins 0.000 claims 1
- 208000011219 Netherton syndrome Diseases 0.000 claims 1
- 102000003827 Plasma Kallikrein Human genes 0.000 claims 1
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 1
- 208000001435 Thromboembolism Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 230000001269 cardiogenic effect Effects 0.000 claims 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 230000003480 fibrinolytic effect Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000002381 testicular Effects 0.000 claims 1
- 208000004043 venous thromboembolism Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361789358P | 2013-03-15 | 2013-03-15 | |
| US61/789,358 | 2013-03-15 | ||
| PCT/US2014/030853 WO2014145986A1 (en) | 2013-03-15 | 2014-03-17 | Multisubstituted aromatic compounds as serine protease inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018038261A Division JP6694458B2 (ja) | 2013-03-15 | 2018-03-05 | セリンプロテアーゼ阻害剤としての多置換芳香族化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513714A JP2016513714A (ja) | 2016-05-16 |
| JP2016513714A5 true JP2016513714A5 (enExample) | 2018-04-19 |
| JP6388634B2 JP6388634B2 (ja) | 2018-09-12 |
Family
ID=51538152
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502572A Active JP6388634B2 (ja) | 2013-03-15 | 2014-03-17 | セリンプロテアーゼ阻害剤としての多置換芳香族化合物 |
| JP2018038261A Active JP6694458B2 (ja) | 2013-03-15 | 2018-03-05 | セリンプロテアーゼ阻害剤としての多置換芳香族化合物 |
| JP2020073902A Pending JP2020121999A (ja) | 2013-03-15 | 2020-04-17 | セリンプロテアーゼ阻害剤としての多置換芳香族化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018038261A Active JP6694458B2 (ja) | 2013-03-15 | 2018-03-05 | セリンプロテアーゼ阻害剤としての多置換芳香族化合物 |
| JP2020073902A Pending JP2020121999A (ja) | 2013-03-15 | 2020-04-17 | セリンプロテアーゼ阻害剤としての多置換芳香族化合物 |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US9533970B2 (enExample) |
| EP (2) | EP3421036B8 (enExample) |
| JP (3) | JP6388634B2 (enExample) |
| KR (1) | KR20150132148A (enExample) |
| CN (5) | CN105324117B (enExample) |
| AU (5) | AU2014232308B2 (enExample) |
| BR (1) | BR112015022340A2 (enExample) |
| CA (2) | CA2901637C (enExample) |
| DK (1) | DK2968297T3 (enExample) |
| ES (2) | ES2853483T3 (enExample) |
| HK (1) | HK1257685A1 (enExample) |
| HR (1) | HRP20182081T1 (enExample) |
| HU (1) | HUE042393T2 (enExample) |
| IL (2) | IL240691B (enExample) |
| LT (1) | LT2968297T (enExample) |
| MX (2) | MX373964B (enExample) |
| NZ (1) | NZ711064A (enExample) |
| PL (2) | PL2968297T3 (enExample) |
| PT (1) | PT2968297T (enExample) |
| RU (2) | RU2678830C2 (enExample) |
| SG (2) | SG10201707480PA (enExample) |
| SI (1) | SI2968297T1 (enExample) |
| TR (1) | TR201819092T4 (enExample) |
| WO (1) | WO2014145986A1 (enExample) |
| ZA (1) | ZA201506295B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2560966B1 (en) * | 2010-03-30 | 2021-01-06 | Verseon International Corporation | Multisubstituted aromatic compounds as inhibitors of thrombin |
| ES2853483T3 (es) * | 2013-03-15 | 2021-09-16 | Verseon Int Corporation | Compuestos aromáticos multisustituidos como inhibidores de la serina proteasa |
| EP2970141B1 (en) | 2013-03-15 | 2020-02-26 | Verseon Corporation | Halogenopyrazoles as inhibitors of thrombin |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| EP3185684A1 (en) | 2014-08-29 | 2017-07-05 | E. I. du Pont de Nemours and Company | Herbicidal triazoles |
| BR112017004704A2 (pt) * | 2014-09-17 | 2018-01-23 | Verseon Corp | composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| EP3262026B1 (en) * | 2015-02-25 | 2020-03-18 | H. Hoffnabb-La Roche Ag | New trifluoromethylpropanamide derivatives |
| US10532995B2 (en) * | 2015-02-27 | 2020-01-14 | Verseon Corporation | Substituted pyrazole compounds as serine protease inhibitors |
| CN106518880B (zh) * | 2015-11-04 | 2018-10-19 | 衡阳师范学院 | 激肽释放酶7小分子抑制剂及其制备方法与用途 |
| CN105218545A (zh) * | 2015-11-04 | 2016-01-06 | 衡阳师范学院 | 激肽释放酶7小分子抑制剂及其制备方法、用途 |
| CA3004095A1 (en) * | 2015-11-09 | 2017-05-18 | Cortexyme, Inc. | Inhibitors of arginine gingipain |
| CN109311824A (zh) * | 2016-03-10 | 2019-02-05 | 北京生命科学研究所 | 激酶抑制剂 |
| RS60600B1 (sr) | 2016-05-31 | 2020-08-31 | Kalvista Pharmaceuticals Ltd | Derivati pirazola kao inhibitori kalikreina plazme |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| IL274557B2 (en) | 2017-11-29 | 2024-09-01 | Kalvista Pharmaceuticals Ltd | Dosage forms comprising a plasma kallikrein inhibitor |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| BR112021000515A2 (pt) | 2018-07-13 | 2021-04-06 | Verseon International Corporation | Composto, pró-fármaco do composto, composição farmacêutica, método para tratar e/ou prevenir uma doença ou distúrbio num indivíduo, comprimido, e, processo de fabricação de um comprimido. |
| EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| JP2022526827A (ja) | 2019-04-11 | 2022-05-26 | アンジオン バイオメディカ コーポレーション | （ｅ）－３－［２－（２－チエニル）ビニル］－１ｈ－ピラゾールの固体形態 |
| CN114206852A (zh) | 2019-08-09 | 2022-03-18 | 卡尔维斯塔制药有限公司 | 血浆激肽释放酶抑制剂 |
| BR102020009679A2 (pt) | 2020-05-14 | 2021-11-23 | Fundação Universidade Federal Do Abc - Ufabc | Anticorpos recombinantes humanos para inibição da calicreína tecidual humana 7 (klk7) e uso em doenças relacionadas ao processo de descamação da pele |
| US20250034112A1 (en) * | 2021-10-13 | 2025-01-30 | Yale University | Improved selective jak2 inhibitors and methods of use |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE627393A (enExample) | 1962-01-23 | |||
| BE793955A (fr) | 1972-01-15 | 1973-07-12 | Merck Patent Gmbh | Arylpiperazines et leur procede de preparation |
| DE2409753A1 (de) | 1974-03-01 | 1975-09-11 | Basf Ag | Substituierte pyrazole |
| US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| PH23506A (en) | 1986-05-23 | 1989-08-16 | Smithkline Beckman Corp | 1-aralkyl-substituted-1,2,4,-triazole-5-thiols as dopamine- -hydroxylase inhibitors |
| JPH089541B2 (ja) | 1988-03-07 | 1996-01-31 | 三井東圧化学株式会社 | ピラゾール類を主成分とする脳浮腫抑制剤 |
| JP2784925B2 (ja) | 1988-09-07 | 1998-08-13 | 日本農薬株式会社 | ３又は５−フェニルピラゾール類又はその塩及び除草剤 |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| JP3810097B2 (ja) | 1993-01-15 | 2006-08-16 | 明治製菓株式会社 | ピロリジン−２−イルカルボニル複素環式化合物誘導体 |
| RU2139281C1 (ru) | 1993-11-30 | 1999-10-10 | Джи Ди Сирл энд Компани | Пиразолилзамещенный бензолсульфонамид или его фармацевтически приемлемая соль, фармацевтическая композиция, способ лечения от воспаления или связанного с воспалением заболевания |
| US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| KR970706813A (ko) | 1994-11-10 | 1997-12-01 | 찰스 홈시 | 단백질 키나아제의 억제물질로서 유용한 제약용 피라졸 조성물(pharmaceutical pyrazole compositions useful as inhibitors of protein kinases) |
| US5733955A (en) | 1995-02-10 | 1998-03-31 | The Goodyear Tire & Rubber Company | Asphalt cement modification |
| JP3663522B2 (ja) | 1995-08-12 | 2005-06-22 | 日本農薬株式会社 | 植物生育調節用組成物及びその使用方法 |
| US5756529A (en) | 1995-09-29 | 1998-05-26 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies |
| EP0802191A4 (en) | 1995-10-13 | 2001-08-01 | Otsuka Kagaku Kk | PYRAZOLE DERIVATIVES AND INSECTICIDE COMPOSITIONS CONTAINING SUCH DERIVATIVES AS ACTIVE INGREDIENTS |
| JPH1023173A (ja) | 1996-07-02 | 1998-01-23 | Nippon Telegr & Teleph Corp <Ntt> | 移動体の遠隔制御システム及び遠隔制御方法 |
| US5792761A (en) | 1996-08-12 | 1998-08-11 | Merck & Co., Inc. | Thrombin inhibitors |
| DE19632773A1 (de) * | 1996-08-14 | 1998-02-19 | Basf Ag | Neue Thrombininhibitoren |
| GB9622370D0 (en) | 1996-10-28 | 1997-01-08 | Merck Sharp & Dohme | Therapeutic agents |
| US5869500A (en) | 1996-12-13 | 1999-02-09 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
| AU730224B2 (en) | 1996-12-23 | 2001-03-01 | Du Pont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| BR9808398A (pt) * | 1997-03-21 | 2000-05-16 | Novartis Ag | Derivados pirazol com atividade herbicida |
| EP1104418A2 (en) | 1998-08-11 | 2001-06-06 | Nihon Bayer Agrochem K.K. | Nematicidal pyrazoles |
| KR20000047461A (ko) | 1998-12-29 | 2000-07-25 | 성재갑 | 트롬빈 억제제 |
| SE9900070D0 (sv) | 1999-01-13 | 1999-01-13 | Astra Ab | New use |
| AR023510A1 (es) | 1999-04-21 | 2002-09-04 | Astrazeneca Ab | Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina. |
| WO2000071536A1 (en) | 1999-05-20 | 2000-11-30 | E.I. Du Pont De Nemours And Company | Heteroaryloxypyrimidine insecticides and acaricides |
| GEP20053476B (en) | 1999-08-12 | 2005-03-25 | Upjohn Co | 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents |
| US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| NZ517828A (en) | 1999-09-17 | 2003-10-31 | Millennium Pharm Inc | Inhibitors having activity against mammalian factor Xa |
| WO2001040223A2 (en) | 1999-12-02 | 2001-06-07 | Novartis Ag | Aminoheterocyclylamides as pesticides and antiparasitic agents |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| JP4316893B2 (ja) | 2001-05-16 | 2009-08-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｓｒｃおよび他のプロテインキナーゼのインヒビター |
| US6589997B2 (en) | 2001-06-29 | 2003-07-08 | North Shore-Long Island Jewish Health System | Small-molecule modulators of hepatocyte growth factor/scatter factor activities |
| SI21097A (sl) | 2001-12-04 | 2003-06-30 | Univerza V Ljubljani | Inhibitorji trombina |
| SE0200198D0 (sv) | 2002-01-23 | 2002-01-23 | Astrazeneca Ab | New use |
| WO2003062206A2 (en) | 2002-01-23 | 2003-07-31 | Arena Pharmaceuticals, Inc. | Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| JP2003313103A (ja) | 2002-02-20 | 2003-11-06 | Sankyo Agro Kk | ４−アシルアミノピラゾール誘導体を有効成分として含有する農薬 |
| GB0214139D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| DE10229070A1 (de) | 2002-06-28 | 2004-01-15 | Merck Patent Gmbh | Phenylderivate 5 |
| AU2003268064A1 (en) | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Oxadiazoles as modulators of metabotropic glutamate receptor-5 |
| WO2004035564A1 (en) * | 2002-10-17 | 2004-04-29 | Syngenta Participations Ag | Pyridine derivatives useful as herbicides |
| US7192976B2 (en) | 2002-12-21 | 2007-03-20 | Angion Biomedica Corporation | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| BR0317659A (pt) * | 2002-12-23 | 2005-12-06 | Aventis Pharma Gmbh | Derivados de pirazol como inibidores de fator xa |
| WO2004058722A1 (en) | 2002-12-24 | 2004-07-15 | Arena Pharmaceuticals, Inc. | Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a |
| US20040147561A1 (en) | 2002-12-27 | 2004-07-29 | Wenge Zhong | Pyrid-2-one derivatives and methods of use |
| JP2004231528A (ja) | 2003-01-28 | 2004-08-19 | Sankyo Agro Kk | アミド誘導体 |
| GB0308318D0 (en) | 2003-04-10 | 2003-05-14 | Merck Sharp & Dohme | Therapeutic agents |
| AU2004236240C1 (en) | 2003-05-01 | 2010-11-04 | Bristol-Myers Squibb Company | Aryl-substituted pyrazole compounds useful as kinase inhibitors |
| ATE410161T1 (de) | 2003-05-02 | 2008-10-15 | Elan Pharm Inc | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen |
| EP1479679A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Triazole-derivatives as factor Xa inhibitors |
| US7223780B2 (en) * | 2003-05-19 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors |
| JP2007513058A (ja) | 2003-09-08 | 2007-05-24 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
| EP1670787B1 (en) | 2003-09-11 | 2012-05-30 | iTherX Pharma, Inc. | Cytokine inhibitors |
| JP2007506741A (ja) | 2003-09-23 | 2007-03-22 | メルク エンド カムパニー インコーポレーテッド | 向代謝性グルタミン酸受容体のピラゾール系調節剤 |
| TW200526588A (en) | 2003-11-17 | 2005-08-16 | Smithkline Beecham Corp | Chemical compounds |
| US20080188527A1 (en) | 2003-12-23 | 2008-08-07 | Cashman John R | Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer |
| WO2005092899A1 (en) | 2004-03-26 | 2005-10-06 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US7235530B2 (en) * | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| AU2006203845A1 (en) | 2005-01-10 | 2006-07-13 | Alexandros Makriyannis | Novel heteropyrrole analogs acting on cannabiniod receptors |
| EP1867331A4 (en) | 2005-04-06 | 2009-04-08 | Takeda Pharmaceutical | TRIAZOLE DERIVATIVE AND USE THEREOF |
| GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| CN100427481C (zh) | 2005-05-26 | 2008-10-22 | 沈阳化工研究院 | 一种芳基醚类化合物及其制备与应用 |
| JP2009518442A (ja) | 2005-12-05 | 2009-05-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性エポキシド加水分解酵素インヒビターとして有益な置換ピラゾール化合物 |
| WO2007129052A1 (en) | 2006-05-03 | 2007-11-15 | Astrazeneca Ab | Pyrazole derivatives and their use as pi3k inhibitors |
| CA2691214A1 (en) | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
| DE102006032824A1 (de) | 2006-07-14 | 2008-01-17 | Bayer Healthcare Ag | Substituierte Indazole |
| EA200900091A1 (ru) | 2006-07-17 | 2009-06-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний |
| AU2007281220B2 (en) * | 2006-07-31 | 2013-08-15 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| CN101495468A (zh) * | 2006-07-31 | 2009-07-29 | 艾克提弗赛特制药股份有限公司 | 血浆激肽释放酶抑制剂 |
| WO2008023235A1 (en) | 2006-08-25 | 2008-02-28 | Pfizer Products Inc. | Pyrazole derivatives as anti-platelet and anti-thrombotic agents |
| EP2096111A1 (en) | 2006-11-20 | 2009-09-02 | Japan Tobacco Inc. | Pyrazoles and use thereof as drugs |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| EP2121619A2 (en) | 2006-11-24 | 2009-11-25 | AC Immune S.A. | Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| US7795249B2 (en) | 2006-12-22 | 2010-09-14 | Millennium Pharmaceuticals, Inc. | Certain pyrazoline derivatives with kinase inhibitory activity |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| WO2008105383A1 (ja) | 2007-02-26 | 2008-09-04 | Toray Industries, Inc. | ピラゾール誘導体およびその医薬用途 |
| GB0714129D0 (en) | 2007-07-19 | 2007-08-29 | Smithkline Beecham Corp | compounds |
| KR20100044829A (ko) | 2007-08-06 | 2010-04-30 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 아미노피라졸 아미드 유도체 |
| KR101559597B1 (ko) | 2007-09-28 | 2015-10-12 | 다케다 야쿠힌 고교 가부시키가이샤 | ５―원 헤테로시클릭 화합물 |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009097141A1 (en) | 2008-01-31 | 2009-08-06 | Joslin Diabetes Center | Methods for treatment of kallikrein-related disorders |
| AU2009212135B2 (en) | 2008-02-07 | 2014-08-21 | Massachusetts Eye & Ear Infirmary | Compounds that enhance Atoh-1 expression |
| EP2300004A4 (en) | 2008-05-15 | 2012-05-30 | Univ Duke | COMPOSITIONS AND METHODS RELATED TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING CONNECTIONS AND OBJECTS THEREFOR |
| CA2724430A1 (en) * | 2008-05-19 | 2009-11-26 | Schering Corporation | Heterocyclic compounds as factor ixa inhibitors |
| WO2010005580A2 (en) | 2008-07-10 | 2010-01-14 | Angion Biomedica Corp. | Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
| EP2321262A1 (de) | 2008-08-14 | 2011-05-18 | Bayer CropScience AG | Insektizide 4-phenyl-1h-pyrazole |
| WO2010020600A1 (en) | 2008-08-19 | 2010-02-25 | Boehringer Ingelheim International Gmbh | Use of dabigatranetexilate for treating patients with pulmonary hypertension |
| WO2010020601A1 (en) | 2008-08-19 | 2010-02-25 | Boehringer Ingelheim International Gmbh | Dabigatran in tumour therapy |
| WO2010020602A1 (en) | 2008-08-19 | 2010-02-25 | Boehringer Ingelheim International Gmbh | Dabigatran for percutaneous interventional cardiac catheterisation |
| JP5767631B2 (ja) | 2009-05-07 | 2015-08-19 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | バニロイド受容体リガンドとしての置換された芳香族カルボキサミドおよび尿素誘導体 |
| EP2560966B1 (en) | 2010-03-30 | 2021-01-06 | Verseon International Corporation | Multisubstituted aromatic compounds as inhibitors of thrombin |
| CN101851207B (zh) | 2010-06-11 | 2012-01-25 | 扬州康伊尔医药科技有限公司 | 抗病毒化合物中间体1-酰基-吡唑-3-羧酸及其制备方法 |
| RS54761B1 (sr) | 2010-06-24 | 2016-10-31 | Gilead Sciences | Pirazolo[1,5-a]pirimidini i-triazini kao antiviralni agensi |
| WO2012020820A1 (ja) | 2010-08-11 | 2012-02-16 | 大正製薬株式会社 | ヘテロアリール－ピラゾール誘導体 |
| CN105360131A (zh) | 2010-11-03 | 2016-03-02 | 陶氏益农公司 | 杀虫组合物和与其相关的方法 |
| WO2012065019A2 (en) * | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of p13k alpha |
| EP2688872A4 (en) | 2011-03-22 | 2014-08-27 | Merck Sharp & Dohme | AMIDOPYRAZOLHEMMER OF INTERLEUKIN RECEPTOR-MEDIATED KINASES |
| US8691861B2 (en) | 2011-04-13 | 2014-04-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| WO2012154880A1 (en) | 2011-05-09 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases |
| SG194847A1 (en) | 2011-05-17 | 2013-12-30 | Plexxikon Inc | Kinase modulation and indications therefor |
| US9371307B2 (en) * | 2011-09-12 | 2016-06-21 | The Johns Hopkins University | Serine protease inhibitors |
| WO2013049591A2 (en) | 2011-09-29 | 2013-04-04 | Verseon Corporation | Dual inhibitor compounds and methods of use thereof |
| EP2797915B1 (en) | 2011-12-27 | 2016-07-13 | Ironwood Pharmaceuticals, Inc. | 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure |
| WO2013111108A1 (en) | 2012-01-27 | 2013-08-01 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| RU2015100942A (ru) | 2012-06-14 | 2016-08-10 | Дайити Санкио Компани, Лимитед | Производное пиперидинилпиразолпиридина |
| TWI498325B (zh) | 2013-01-18 | 2015-09-01 | Hoffmann La Roche | ３－取代吡唑及其用途 |
| EP2970141B1 (en) | 2013-03-15 | 2020-02-26 | Verseon Corporation | Halogenopyrazoles as inhibitors of thrombin |
| ES2853483T3 (es) * | 2013-03-15 | 2021-09-16 | Verseon Int Corporation | Compuestos aromáticos multisustituidos como inhibidores de la serina proteasa |
| PL3102568T3 (pl) | 2014-02-06 | 2019-01-31 | Heptares Therapeutics Limited | Bicykliczne związki aza w postaci agonistów receptorów muskarynowych m1 |
| BR112017004704A2 (pt) * | 2014-09-17 | 2018-01-23 | Verseon Corp | composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo |
-
2014
- 2014-03-17 ES ES18189634T patent/ES2853483T3/es active Active
- 2014-03-17 PT PT14764515T patent/PT2968297T/pt unknown
- 2014-03-17 EP EP18189634.1A patent/EP3421036B8/en active Active
- 2014-03-17 DK DK14764515.4T patent/DK2968297T3/en active
- 2014-03-17 KR KR1020157024792A patent/KR20150132148A/ko not_active Ceased
- 2014-03-17 US US14/776,612 patent/US9533970B2/en active Active - Reinstated
- 2014-03-17 CA CA2901637A patent/CA2901637C/en active Active
- 2014-03-17 PL PL14764515T patent/PL2968297T3/pl unknown
- 2014-03-17 JP JP2016502572A patent/JP6388634B2/ja active Active
- 2014-03-17 SG SG10201707480PA patent/SG10201707480PA/en unknown
- 2014-03-17 WO PCT/US2014/030853 patent/WO2014145986A1/en not_active Ceased
- 2014-03-17 HU HUE14764515A patent/HUE042393T2/hu unknown
- 2014-03-17 CN CN201480015684.0A patent/CN105324117B/zh active Active
- 2014-03-17 SI SI201431006T patent/SI2968297T1/sl unknown
- 2014-03-17 HR HRP20182081TT patent/HRP20182081T1/hr unknown
- 2014-03-17 RU RU2015144151A patent/RU2678830C2/ru not_active IP Right Cessation
- 2014-03-17 MX MX2015012867A patent/MX373964B/es active IP Right Grant
- 2014-03-17 BR BR112015022340A patent/BR112015022340A2/pt not_active Application Discontinuation
- 2014-03-17 SG SG11201506449QA patent/SG11201506449QA/en unknown
- 2014-03-17 LT LTEP14764515.4T patent/LT2968297T/lt unknown
- 2014-03-17 AU AU2014232308A patent/AU2014232308B2/en active Active
- 2014-03-17 RU RU2019101889A patent/RU2019101889A/ru not_active Application Discontinuation
- 2014-03-17 CA CA3051327A patent/CA3051327A1/en not_active Abandoned
- 2014-03-17 TR TR2018/19092T patent/TR201819092T4/tr unknown
- 2014-03-17 CN CN201910277176.4A patent/CN110101699A/zh active Pending
- 2014-03-17 CN CN201810175722.9A patent/CN108354933A/zh active Pending
- 2014-03-17 NZ NZ711064A patent/NZ711064A/en unknown
- 2014-03-17 PL PL18189634T patent/PL3421036T3/pl unknown
- 2014-03-17 EP EP14764515.4A patent/EP2968297B1/en active Active
- 2014-03-17 ES ES14764515T patent/ES2702182T3/es active Active
- 2014-03-17 CN CN201910277094.XA patent/CN110179795A/zh active Pending
- 2014-03-17 CN CN201910277180.0A patent/CN110101700A/zh active Pending
-
2015
- 2015-08-20 IL IL240691A patent/IL240691B/en not_active IP Right Cessation
- 2015-08-27 ZA ZA2015/06295A patent/ZA201506295B/en unknown
- 2015-09-14 MX MX2020004183A patent/MX2020004183A/es unknown
-
2016
- 2016-11-17 US US15/354,756 patent/US9687479B2/en active Active
-
2017
- 2017-05-25 US US15/605,566 patent/US10058541B2/en active Active
- 2017-09-04 AU AU2017225000A patent/AU2017225000B2/en active Active
- 2017-11-07 AU AU2017258834A patent/AU2017258834B2/en not_active Ceased
- 2017-11-13 US US15/811,220 patent/US10251872B2/en active Active
-
2018
- 2018-01-31 AU AU2018200736A patent/AU2018200736B2/en not_active Ceased
- 2018-03-05 JP JP2018038261A patent/JP6694458B2/ja active Active
-
2019
- 2019-01-03 HK HK19100049.0A patent/HK1257685A1/en unknown
- 2019-01-10 US US16/245,075 patent/US20190142813A1/en not_active Abandoned
-
2020
- 2020-02-05 IL IL272474A patent/IL272474A/en unknown
- 2020-03-05 AU AU2020201668A patent/AU2020201668A1/en not_active Abandoned
- 2020-04-17 JP JP2020073902A patent/JP2020121999A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513714A5 (enExample) | ||
| RU2019101889A (ru) | Полизамещенные ароматические соединения в качестве ингибиторов сериновых протеаз | |
| JP2017528486A5 (enExample) | ||
| ES2949404T3 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP | |
| US11225477B2 (en) | Inhibitors of influenza virus replication, application methods and uses thereof | |
| CN104169257B (zh) | 用作smac模拟物的6‑炔基吡啶 | |
| TWI400234B (zh) | 作為組織胺ｈ4受體調節劑之苯并咪唑-２-基嘧啶類及吡類 | |
| CN104302638B (zh) | 用于抑制abl1、abl2和bcr-abl1的活性的苯甲酰胺衍生物 | |
| HRP20250373T1 (hr) | Inhibitori parp1 | |
| JP2025090726A5 (enExample) | ||
| JP2017535589A (ja) | ２−アミノピリミジン系化合物およびその薬物組成物と使用 | |
| JP2021523887A (ja) | ＸＩＩａ因子インヒビター | |
| CN107001363B (zh) | 二氢吲嗪酮衍生物 | |
| RU2017112739A (ru) | Пиразолил-замещенные пиридоновые соединения как ингибиторы сериновых протеаз | |
| JP2014193925A5 (enExample) | ||
| CN102548965A (zh) | 取代酰胺化合物 | |
| US20130183268A1 (en) | Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions | |
| JP2016512243A5 (enExample) | ||
| MX2020012034A (es) | Inhibidores de furina. | |
| KR20190092545A (ko) | 인플루엔자 바이러스 복제의 억제제 및 이의 용도 | |
| CA2900292A1 (en) | 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions | |
| CR20220096A (es) | Proteínas de fusión terapéuticas | |
| El Malah et al. | Click synthesis, anticancer activity and molecular docking studies on pyridazinone scaffolds | |
| HRP20110054T1 (hr) | Derivat triazolona | |
| EP3914585A1 (en) | Sulfonimidamide compounds and compositions for treating conditions associated with nlrp activity |